Larvol Delta - Preclinical-Characterization-of-SGT003-a-Novel-Bispecific-Antibody-Targeting-CCR8-and-CTLA4-for-Advanced-Solid-Tumor-Immunotherapy

SGT003 - Beijing Sungen Biomedical Technology

https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal_2/print/presentation/3960

Zhiwei Sun

Jul 17, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next